EFFICACY OF NICORANDIL IN THE TREATMENT OF PATIENTS WITH CORONARY HEART DISEASE
Issue:
12
Year:
2017
The paper reviews researches on the use the adenosine triphosphate-sensitive potassium channel activator nicorandil in the treatment of coronary heart disease.
Keywords:
cardiology
nicorandil
exertional angina
quality of life
cardioprotection
prognosis of coronary heart disease
References:
- Ageev F.T., Smirnova M.D., Fofanova T.V. Povyshenie priverzhennosti k terapii: «Delo tehniki»? // Serdechnaja nedostatochnost'. – 2011; 12 (4): 66.
- Voronina V.P., Martsevich, S.Ju., Kutishenko N.P. i dr. Otsenka antiishemicheskogo i antianginal'nogo effektov nikorandila s pomosch'ju nagruzochnyh testov na tredmile v ramkah issledovanija KVAZAR // RKZh. – 2017; 3: 97–103.
- Giljarevskij S.R., Orlov V.A., Seredenina E.M. Samokontrol' i samolechenie bol'nyh s hronicheskoj serdechnoj nedostatochnost'ju: granitsy effektivnosti i bezopasnosti // Serdechnaja nedostatochnost'. – 2002; 3 (5): 237–44.
- Giljarevskij S.R., Rezvan V.V., Kuz'mina I.M. i dr. Sovremennye podhody k protivoishemicheskoj terapii bol'nyh so stabil'nym techeniem ishemicheskoj bolezni serdtsa // RMZh. – 2014; 12: 928.
- Egorov V.A., Shilova E.V., Martsevich S.Ju. Vybor terapii nitratami u bol'nyh stabil'noj stenokardiej naprjazhenija: sravnitel'noe issledovanie obychnyh tabletok izosorbida dinitrata i razlichnyh lekarstvennyh form izosorbida5mononitrata // Rats. farmakoter. i kardiol. – 2008; 2: 19–22.
- Eshihisa A., Sato Ju., Vatanabe S. i dr. Snizhenie smertnosti u bol'nyh s serdechnoj nedostatochnost'ju ishemicheskoj etiologii, prinimajuschih nikorandil // Consilium Medicum. – 2017; 19 (10): 74–8.
- Zhiljaev E.V. Nitraty v lechenii stabil'noj stenokardii: novye gorizonty // Sonsilium Medicum. – 2010; 1: 14–8.
- Kardiovaskuljarnaja profilaktika. Natsional'nye rekomendatsii. VNOK // Kardiovask. ter. i profilakt. – 2011; 6 (Pril. 2): 57.
- Karpov Ju.A., Sorokin E.V.. Stabil'naja ishemicheskaja bolezn' serdtsa: strategija i taktika lechenija. 3-e izd. / M., 2012.
- Martsevich, S.Ju., Kutishenko N.P. i dr. Sravnitel'naja otsenka antianginal'noj effektivnosti i bezopasnostipreparata nikorandil na fone bazisnoj terapii β-adrenoblokatorami u bol'nyh ishemicheskoj bolezn'ju serdtsa so stabil'noj stenokardiej // Kardiologija. – 2016; 10: 30–4.
- Martsevich S.Ju., Kutishenko N.P., Egorov V.A. i dr. Sravnitel'noe issledovanie effektivnosti i perenosimosti antianginal'nyh preparatov razlichnyh grupp – nitrovazodilatatora (izosorbida-5-mononitrat prolongirovannogo dejstvija) i beta-blokatora s vazodilatirujuschim dejstviem (nebivolol) // Rats. farmakoter. v kardiol. – 2011; 7 (5): 555–60.
- Martsevich S.Ju., Navasardjan A.R., Kutishenko N.P. i dr. Otsenka priverzhennosti k priemu novyh oral'nyh antikoaguljantov u patsientov s fibrilljatsiej predserdij po dannym registra profil' // RFK. – 2014; 10 (6): 625–307.
- Martsevich S.Ju., Lukina Ju.V., Kutishenko N.P. i dr. Nabljudatel'noe mnogotsentrovoe issledovanie primenenija nikorandila u bol'nyh stabil'noj ishemicheskoj bolezn'ju serdtsa s vysokim serdechno-sosudistym riskom (NIKEJa): dizajn, pervye rezul'taty // Ros. kardiol. zhurn. – 2017; 9 (149): 82–9.
- Oganov R.G., Mamedov M.N. Natsional'nye klinicheskie rekomendatsii VNOK / M.: «Silitseja-Poligraf», 2009; 528 s.
- Rubrikator klinicheskih rekomendatsij i svjazannyh dokumentov [Elektronnyj resurs] Rossijskoe kardiologicheskoe obschestvo; Natsional'noe obschestvo po izucheniju ateroskleroza; Natsional'noe obschestvo po aterotrombozu. Elektron.dan. / M.: Klinicheskie rekomendatsii. Stabil'naja ishemicheskaja bolezn' serdtsa Rezhim dostupa: http://cr.rosminzdrav.ru/schema.html?id=133#/text
- Rjabihin E.A., Mozhejko M.E., Krasil'nikova Ju.A. i dr. Dopolnitel'nye vozmozhnosti v lechenii ishemicheskoj bolezni serdtsa, oslozhnennoj hronicheskoj serdechnoj nedostatochnost'ju s nizkoj fraktsiej vybrosa levogo zheludochka // Serdechnaja nedostatochnost'. – 2016; 17 (1): 3–9.
- Sizova Zh.M., Zaharova V.L., Kozlova N.V. i dr. Vlijanie aktivatora kalievyh kanalov nikorandila na kachestvo zhizni bol'nyh ishemicheskoj bolezn'ju serdtsa so stabil'noj stenokardiej naprjazhenija // Kardiologija. – 2016; 56 (6): 57–62.
- Aizawa K., et al. Nicorandil prevents sirolimus-induced production of reactive oxygen species, endothelial dysfunction, and thrombus formation // J. Pharmacol. Sci. – 2015; 127 (3): 284–91.
- Eguchi Y., Takahari Y., Higashijima N. et al. Nicorandil Attenuates FeCl3-Induced Thrombus Formation Through the Inhibition of Reactive Oxygen Species Production // Circ. J. – 2009; 73 (3): 554–61.
- IONA study Grup. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA): randomized trial // Lancet. – 2002; 359 (9314): 1269–75.
- Izumiya Y., Kojima S., Araki S. et al. Long-term use of oral nicorandil stabilizes coronary plaque in patients with stable angina pectoris // Atherosclerosis. – 2011; 214 (2): 415–21.
- Fischer M., Stedman M., Lii J. et al. Primary medication non-adherence: analysis of195,930 electronic prescriptions // J. Gen Intern. Med. – 2010; 25 (4): 284–90.
- Fihn S. et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease // Circulation. – 2012; 126: e354–e471. https://doi.org/10.1161/CIR.0b013e318277d6a0
- Fox K., Garcia M., Ardissino D. et al. Guidelines on the management of stable angina pectoris: executive summary: the task Force on the Management of stable Angina Pectoris of the European society of Cardiology // Eur. Heart J. – 2006; 27 (11): 1341–81.
- Horinaka S. Use of Nicorandil in Cardiovascular Disease and Its Optimization // Drugs. – 2011; 71 (9): 1105.
- Horinaka S., Yabe A., Yagi H. et al. Effects of nicorandil on cardiovascular events in patients with coronary artery disease in the Japanese Coronary Artery Disease (JCAD) study // Circ. J. – 2010; 74: 503–9.
- Kasama S., Toyama T., Sumino H. et al. Long-term nicorandil therapy improves cardiac sympathetic nerve activity after reperfusion therapy in patients with first acutemyocardial infarction // J. Nucl. Med. – 2007; 48 (10): 1676–82.
- Kasama S., Toyama T., Hatori T. et al. Comparative effects of nicorandil with isosorbide mononitrate on cardiac sympathetic nerve activity and left ventricular function in patients with ischemic cardiomyopathy // Am. Heart J. – 2005; 150 (3): 477.
- Kinoshita M., Sakai K. Pharmacology and therapeutic effects of nicorandil // Cardiovasc. Drugs Ther. – 1990; 4 (4): 1075–88.
- Krumenacker M., Roland E. Clinical profile of nicorandil: an overview of its hemodynamic properties and therapeutic efficacy // J. Cardiovasc. Pharmacol. – 1992; 20 (Suppl. 3): 93–102.
- Lauer M., D’Agostino R. (Sr.). The randomized registry trial — the next disruptive technology in clinical research? // N. Engl. J. Med. – 2013; 369 (17): 1579–81.
- Markham A., Plosker G., Goa K. Nicorandil. An updated review of its use in ischaemic heart disease with emphasis on its cardioprotective effects // Drugs. – 2000; 60 (4): 955–74.
- Montalescot G., Sechtem U., Achenbach S. et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force of the European Society of Cardiology // Eur. Heart J. – 2013; 34 (38): 2949–3003.
- Sakamoto T., Kaikita K., Miyamoto S. et al. Effects of nicorandil on endogenous fibrinolytic capacity in patients with coronary artery disease // Circ. J. – 2004; 68 (3): 232–5.
- Sakata Y., Nakatani D., Shimizu M. et al. Oral treatment with nicorandil at discharge is associated with reduced mortality after acute myocardial infarction // J. Cardiol. – 2012; 59 (1): 14–21.
- Sekiya M., Sato M., Funada J. et al. Effects of the long-term administration of nicorandil on vascular endothelial function and the progression of arteriosclerosis // J. Cardiovasc. Pharmacol. – 2005; 46 (1): 63–7.
- Patel D., Purcell H., Fox K. On behalf of the CESAR 2 investigation. Cardioprotection by